Compare ResMed Inc. (RMD) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Upstart Holdings Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Upstart Holdings Inc trades at $26.07 (market cap $2.63B). The key difference: ResMed Inc. is far larger — about 12.1× Upstart Holdings Inc's market cap, and ResMed Inc. pays a 1.19% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| RMD | UPST | |
|---|---|---|
Market Cap | $31.89B | $2.63B |
Sector | Health | Financials |
52-Week High | $283.28 | $68.11 |
52-Week Low | $182.82 | $24.22 |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Upstart Holdings (UPST) trades at $26.98, down 3.81% on the day, reflecting bearish technical momentum and recent earnings misses. The stock shows oversold conditions with an RSI of 18.98, while fundamentals indicate a turnaround with 2025 net income of $53.60M on $1.02B revenue, marking its first annual profit. Analyst sentiment is mixed with a 45.46% buy rating and $47.20 consensus target, but insider selling and weak cash flow from operations pose concerns.
The outlook hinges on execution in personal loan growth and AI lending efficiency, but risks include high debt-to-asset ratio of 61.48% and macroeconomic sensitivity. Near-term resistance at $28 challenges upside, while support at $26 may stabilize declines if earnings improve in Q3 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
